J&J is pausing recruitment for its clinical trial of a coronavirus disease 2019 vaccine; racial bias found in algorithms used nationwide in health-cost analytics software; Americans stockpile food and other essentials amid resurging pandemic fears.
Announced yesterday, Johnson & Johnson (J&J) said it is temporarily pausing recruitment and dosing for its coronavirus disease 2019 (COVID-19) vaccine candidate clinical trial after an unexplained illness in a study participant. Reported by POLITICO, the case, part of J&J’s phase 3 ENSEMBLE trial, is being reviewed by the independent drug safety monitoring board, with no further information on the patient being released. The company cautioned that adverse events, even serious ones, typically occur in any clinical study.
Reported today, a STAT investigation found that a common method of using analytics software is infusing racial bias into decision-making on who should receive stepped-up care. The study, which analyzed medical services targeted to patients who need them most, additionally found multiple algorithms across several hospitals in the United States, signaling a systemic issue as opposed to a singular event. Researchers note that the bias can produce significant differences in assessing patients’ need for special care to manage conditions like hypertension and diabetes.
Reported by USA Today, amid reports of surges in COVID-19 cases nationwide, slightly more than half of Americans said in a recent poll they have or plan to stockpile food and other essentials. Principal reasons for this include the millions who continue to work or attend school remotely, as well as fears of a resurgent pandemic. As of October 2, COVID-19 cases in the United States were at their highest in almost 2 months, and in the past week, the average grocery bill has risen 11%.
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More